Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02890979 · ClinicalTrials.gov registry record · NA
Swallowable Sponge Cell Sampling Device and Next Generation Sequencing in Detecting Esophageal Cancer in Patients With Low or High Grade Dysplasia, Barrett Esophagus, or Gastroesophageal Reflux Disease
A NA study of Esophageal Adenocarcinoma and Barrett Esophagus, sponsored by OHSU Knight Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT02890979 is a NA study of Esophageal Adenocarcinoma and Barrett Esophagus that has completed, run by OHSU Knight Cancer Institute. The registered enrollment target is 11 participants, below the 308-participant average among 43 other Esophageal Adenocarcinoma trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02890979, a NA study of Esophageal Adenocarcinoma and Barrett Esophagus, has completed, sponsored by OHSU Knight Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot clinical trial studies how well a swallowable sponge cell sampling device and next generation sequencing work in detecting esophageal cancer in patients with low or high grade dysplasia, Barrett esophagus, or gastroesophageal reflux disease. Checking biomarkers in abnormal esophageal cells using a swallowable sponge cell sampling device and next generation sequencing may improve diagnosis and treatment of esophageal cancer.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Laboratory Biomarker Analysis
- OTHER Cytology Specimen Collection Procedure
- DEVICE Swallowable Sponge Cell Sampling Device
Study Locations (1)
Oregon
- OHSU Knight Cancer Institute - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2016-08-03 |
| Est. Completion | 2017-10-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02890979
The ClinicalTrials.gov registry entry for NCT02890979 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 308-participant average among 43 other Esophageal Adenocarcinoma trials with a reported enrollment target (96% lower). The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Esophageal Adenocarcinoma appearing as the primary indexed condition, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.
NCT02890979 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT02890979 about?
NCT02890979 is a clinical study titled "Swallowable Sponge Cell Sampling Device and Next Generation Sequencing in Detecting Esophageal Cancer in Patients With Low or High Grade Dysplasia, Barrett Esophagus, or Gastroesophageal Reflux Disease". This pilot clinical trial studies how well a swallowable sponge cell sampling device and next generation sequencing work in detecting esophageal cancer in patients with low or high grade dysplasia, Barrett esophagus, or gastroesophageal reflux disease. Checking biomarkers in abnormal esophageal cell...
What is the current status of trial NCT02890979?
This trial is currently completed. It is a NA study. The enrollment target is 11 participants. The study started on 2016-08-03. Estimated completion is 2017-10-10.
What conditions does trial NCT02890979 study?
This clinical trial studies the following conditions: Esophageal Adenocarcinoma, Barrett Esophagus, Gastroesophageal Reflux Disease, Esophageal Squamous Cell Carcinoma, Dysplasia.
What interventions are being tested in trial NCT02890979?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Laboratory Biomarker Analysis (OTHER), Cytology Specimen Collection Procedure (OTHER), Swallowable Sponge Cell Sampling Device (DEVICE).
Who is sponsoring clinical trial NCT02890979?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02890979 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma
RECRUITING · NA
-
Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples
RECRUITING · NA
-
Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance
RECRUITING · NA
-
Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
RECRUITING · NA
-
Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms
RECRUITING · NA
-
Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal Microbiome
COMPLETED · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.